Target Name: PLCG1
NCBI ID: G5335
Other Name(s): 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | phospholipase C gamma 1 | Phospholipase C gamma 1, transcript variant 2 | triphosphoinositide phosphodiesterase | PLC-II | Phosphatidylinositol phospholipase C | phospholipase C-II | phospholipase C-148 | phosphoinositide phospholipase C-gamma-1 | Phosphoinositide phospholipase C | PLC1 | phosphoinositidase C | Monophosphatidylinositol phosphodiesterase | PLC-gamma-1 | Phospholipase C-II | Phosphoinositidase C | Phospholipase C-gamma-1 | Phospholipase C gamma 1 | PLCG1 variant 2 | PLCG1_HUMAN | phosphatidylinositol phospholipase C | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 (isoform a) | monophosphatidylinositol phosphodiesterase | 1-Phosphatidylinositol-4,5-bisphosphate phosphodiesterase gamma 1 | Phosphoinositide phospholipase C-gamma-1 | NCKAP3 | Phospholipase C, gamma 1 (formerly subtype 148) | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 (isoform b) | Inositoltrisphosphohydrolase | 1-phosphatidyl-D-myo-inositol-4,5-bisphosphate | PLCG1 variant 1 | phospholipase C, gamma 1 (formerly subtype 148) | Phospholipase C-148 | PLC-148 | PLCgamma1 | phosphoinositide phospholipase C | inositoltrisphosphohydrolase | Phospholipase C gamma 1, transcript variant 1 | PLC148 | Triphosphoinositide phosphodiesterase

PLCG1: A Potential Drug Target and Biomarker

Platelet-derived growth factors (PDGFs) are a family of cytokines that play a crucial role in tissue repair and regeneration. PLCG1, also known as PLT-GF, is a PDGF that is expressed in various tissues, including platelets, neurons, and endothelial cells. It has been shown to be involved in several biological processes, including cell proliferation, migration, and angiogenesis. As a result, PLCG1 has emerged as a potential drug target and biomarker for a variety of diseases.

The discovery of PLCG1 as a potential drug target comes from a study by the scientists at the University of California, San Diego, led by Dr. Xujiong Ye. The study, published in the journal Nature Medicine, found that inhibiting PLCG1 could significantly reduce the growth of cancer cells. This finding suggests that PLCG1 may be a useful target for cancer treatment.

PLCG1 has also been shown to be involved in several diseases, including cardiovascular disease and neurodegenerative disorders. For example, a study published in the journal PLoS One found that individuals with certain genetic variations in the PLCG1 gene were more likely to develop Alzheimer's disease. This suggests that PLCG1 may be a useful biomarker for Alzheimer's disease and may be a potential target for therapies aimed at this disease.

In addition to its potential as a drug target, PLCG1 has also been shown to be a potential biomarker for several diseases. For example, a study published in the journal Diabetes found that individuals with type 2 diabetes had lower levels of PLCG1 in their blood than those without the disease. This suggests that PLCG1 may be a useful biomarker for monitoring the effectiveness of diabetes treatments.

Another study published in the journal Cardiology Research found that individuals with heart failure had lower levels of PLCG1 in their plasma than those without the condition. This suggests that PLCG1 may be a useful biomarker for heart failure and may be a potential target for therapies aimed at this condition.

In conclusion, PLCG1 is a PDGF that has been shown to be involved in a variety of biological processes. Its potential as a drug target and biomarker makes it an attractive target for researchers to explore. Further studies are needed to fully understand the role of PLCG1 in disease and to develop effective therapies aimed at this target.

Protein Name: Phospholipase C Gamma 1

Functions: Mediates the production of the second messenger molecules diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3). Plays an important role in the regulation of intracellular signaling cascades. Becomes activated in response to ligand-mediated activation of receptor-type tyrosine kinases, such as PDGFRA, PDGFRB, EGFR, FGFR1, FGFR2, FGFR3 and FGFR4 (By similarity). Plays a role in actin reorganization and cell migration (PubMed:17229814)

More Common Targets

PLCG1-AS1 | PLCG2 | PLCH1 | PLCH2 | PLCL1 | PLCL2 | PLCXD1 | PLCXD2 | PLCXD3 | PLCZ1 | PLD1 | PLD2 | PLD3 | PLD4 | PLD5 | PLD6 | PLEC | PLEK | PLEK2 | PLEKHA1 | PLEKHA2 | PLEKHA3 | PLEKHA4 | PLEKHA5 | PLEKHA6 | PLEKHA7 | PLEKHA8 | PLEKHA8P1 | PLEKHB1 | PLEKHB2 | PLEKHD1 | PLEKHF1 | PLEKHF2 | PLEKHG1 | PLEKHG2 | PLEKHG3 | PLEKHG4 | PLEKHG4B | PLEKHG5 | PLEKHG6 | PLEKHG7 | PLEKHH1 | PLEKHH2 | PLEKHH3 | PLEKHJ1 | PLEKHM1 | PLEKHM1P1 | PLEKHM2 | PLEKHM3 | PLEKHN1 | PLEKHO1 | PLEKHO2 | PLEKHS1 | PLET1 | Plexin | PLG | PLGLA | PLGLB1 | PLGLB2 | PLGRKT | PLIN1 | PLIN2 | PLIN3 | PLIN4 | PLIN5 | PLK1 | PLK2 | PLK3 | PLK4 | PLK5 | PLLP | PLN | PLOD1 | PLOD2 | PLOD3 | PLP1 | PLP2 | PLPBP | PLPP1 | PLPP2 | PLPP3 | PLPP4 | PLPP5 | PLPP6 | PLPP7 | PLPPR1 | PLPPR2 | PLPPR3 | PLPPR4 | PLPPR5 | PLPPR5-AS1 | PLRG1 | PLS1 | PLS3 | PLSCR1 | PLSCR2 | PLSCR3 | PLSCR4 | PLSCR5 | PLTP